SENSEI BIOTHER. DL -,0001

Sensei Biotherapeutics announced it is halting clinical development of its cancer therapeutic Solnerstotug and has initiated a comprehensive strategic review to maximize shareholder value. The company is considering options such as asset sales, licensing agreements, partnerships, a sale, a merger or an orderly wind-down and plans staff reductions to preserve liquidity. A small team will remain to meet regulatory and financial obligations; no timetable for the review was given and completion of a transaction is not guaranteed. The stock reacted positively and rose in trading after the announcement. » More on de.investing.com

Sensei Biotherapeutics shares fell 8.7% in premarket trading after results from the dose‑expansion part of the phase‑1/2 trial of solnerstotug were released. In the study of 64 patients, 6 of 35 efficacy‑evaluable patients with “hot” tumors showed a clinical response, all at the higher 15 mg/kg dose; no objective responses were seen at 3 mg/kg. Six‑month PFS in patients with prior PD-(L)1 therapy was 37% overall, 50% at 15 mg/kg and 24% at 3 mg/kg. Sensei reported a favorable safety profile with few mild cytokine release events and plans two phase‑2 studies in 2026, dependent on FDA feedback and financing. » More on de.investing.com

Sensei Biotherapeutics is presenting clinical data on its lead product candidate, Solnerstotug, tested in patients with advanced solid tumors at the ESMO Congress 2025. The company also announced a 1-for-20 reverse stock split and a reduction in authorized shares to meet Nasdaq listing requirements. Analysts view the company's innovative approach positively and maintain a buy recommendation. » More on de.investing.com